Research investigator will also treat kidney patients
DANVILLE, PA -- Nephrologist Kevin Ho, M.D. (right), has joined Geisinger as a research investigator in the Geisinger Kidney Health Research Institute and as a kidney disease specialist, treating patients at Geisinger Medical Center in Danville.
Dr. Ho studies kidney disease at a molecular level and is interested in combining patient medical histories with detailed genomic data — becoming available through the MyCode Community Health Initiative — to identify the particular molecular pathways affected in subgroups of kidney disease patients to better target individualized treatments to patients.
Dr. Ho said he was excited to join Geisinger, both to treat patients and to pursue his research interests.
“Geisinger is ideally suited for this research work given its well-developed focus on personalized medicine and translational science as illustrated by its commitment to bioinformatics and genomic medicine,” Dr. Ho said.
Dr. Ho joins Geisinger from the University of Pittsburgh School of Medicine, where he served as an associate professor of medicine in the school’s renal-electrolyte division and its Clinical and Translational Science Institute.
A native of Cleveland, Ohio, Dr. Ho received his undergraduate degree in biological sciences from Harvard University in 1982 and his doctor of medicine degree from Columbia University in New York in 1987.
“We are pleased to have Dr. Ho join our team here at the Geisinger nephrology department and believe his experience in the care of patients with kidney disease will be a significant asset to our patients,” said Evan R. Norfolk, M.D., director of the nephrology department.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.